Policy & Regulation
Acquist Therapeutics names new directors
28 May 2020 -

Acquist Therapeutics Inc, a biopharmaceutical company involved in new treatment for patients with inflammatory diseases, has named Thomas P Haverty, MD, and John R Redman, MD as its new directors, it was reported on Wednesday.

Dr Haverty has over 30 years of pharmaceutical and biotechnology experience. He has headed teams in clinical research and operations for various drug classes and medical indications. Presently, he is the interim chief medical officer at Eloxx Pharmaceuticals, where he oversees clinical studies of eukaryotic read-through agents in rare hereditary diseases. He also held leadership roles at Immusan T, Merck Research Labs, Schering-Plough Research Institute, and Johnson & Johnson's Pharmaceutical Research Institutes.

Dr Redman has more than 30 years of experience in the biopharmaceutical industry, with leadership roles in clinical development, medical affairs, and regulatory oversight and strategy. He has supervised clinical programs that led to regulatory approvals of over 15 new drugs. Presently, he is the chief executive officer of Proteus Ventures LLC. He has also served as a clinical consultant for Takeda Pharmaceuticals, Jounce Therapeutics, Sanofi Genzyme, and Curis. He earlier held leadership development roles at ICON, Incyte, Celator, and Wyeth Ayerst (now Pfizer).



Related Headlines